The stock market is made up of thousands of companies, most of which do a good job of creating value for their shareholders. But it wasn't that long ago that we witnessed some of the most egregious abuses of fiduciary responsibility in history. Over the past decade, we watched as numerous companies took big hits from scandals.

Adelphia Communications collapsed under the weight of $2.3 billion in off-balance sheet debt and questionable spending on personal expenses that eventually led to the conviction of its founder and his son for conspiracy and bank fraud. Likewise, Tyco International (NYSE: TYC) shareholders suffered mightily after then-CEO Dennis Kozlowski misappropriated company funds. Nine years later, Tyco shares still haven't recovered from their plunge in 2002 as the scandal came to light.

The scary part is that there are still bad apples out there that could spoil the bunch for everyone. New regulations have curbed some of the most obscene abuses of power, such as John Thain spending $1.2 million decorating his office while his company spiraled downward in the run-up to the financial crisis. Still, there exists a subset of companies that frankly don't care about you or your money -- and you may want to think twice before investing in these stocks.

Clinical triage
Long before Israeli-based Protalix BioTherapeutics (AMEX: PLX) and Pfizer (NYSE: PFE) partnered in an attempt to bring a treatment for Gaucher disease to market, Protalix was busy raising the heart rates of its shareholders with secondary offerings. In the course of five years, Protalix shareholders watched as the number of outstanding shares soared from just under 19 million all the way to 81 million.

Even worse, in October 2007, with Protalix's stock having closed the previous day at $36.36 a share, the company brought to market a secondary share offering, which was priced at $5. Yes, you are reading that correctly -- five dollars, or more than an 85% discount! The following day, the stock price dove to $6.31 and has never come close to recovering. To top this off, in addition to all the new company stock offerings, insiders have systemically sold off their own shares, while I found only one outright insider purchase. Talk about a company that doesn't care about you or your money!

Pass the caviar
Apathy for shareholders can come in many forms, but nothing is potentially as scary as a CEO gone wild. Shareholders of Abercrombie & Fitch (NYSE: ANF) and Rite-Aid (NYSE: RAD) may know what I'm talking about here as their CEOs seem to have a major disconnect between their fiduciary responsibility to shareholders and their own wallets.

Abercrombie & Fitch CEO Michael Jeffries is no stranger to the spotlight. He's been pocketing healthy compensation packages for years despite heading a retailer that's had its fair share of ups and downs. What really put shareholders into an uproar was news last year that the company cut Jeffries a check for $4 million just to curtail his usage of the company's private jet. Needless to say, it didn't go over well with shareholders. Not to be outdone, Jeffries also announced in August that he intended to sell as much as 1.79 million shares of his stock.

Since its purchase of Eckerd in 2007, Rite-Aid has been unable to tackle its long-term debt, which now stands at $6.1 billion. But that hasn't stopped newly appointed CEO John Standley's reported total compensation from rising from $2.3 million in its fiscal 2009 year to $4.5 million in fiscal 2010. Rite-Aid remains unprofitable and has struggled just to maintain the minimum listing requirements on the NYSE, yet its CEO appears to be looking in the other direction.

No soup for you
The next company on my list may come as a complete shock to you: Apple (Nasdaq: AAPL). Now relax, pick up the other half of your jaw and read on. It's not that Apple hasn't done a good job of creating shareholder value throughout the years. In fact, only a handful of companies have outperformed Apple's stock over the past decade. Apple could practically snap its fingers when it's ready to introduce a new product, like it did yesterday when it unveiled the iPad 2, and command consumers to buy. But in the end, Apple doesn't care about its investors enough to pay a dividend.

Apple generated a mind-boggling $9.8 billion in operating cash flow last quarter, but shareholders aren't going to see a penny of it. Apple has $27 billion in cash and an additional $32.7 billion in long-term marketable securities, but don't expect the company to begin paying a dividend or buying back shares anytime soon.

Microsoft (Nasdaq: MSFT), on the other hand, has generated more than $25 billion in operating cash flow over the past 12 months and now pays out a $0.16 per share quarterly dividend to shareholders, as well as buying back significant amounts of its own stock. This isn't to say Apple isn't looking to grow as a company, but I do question whether it cares about its shareholders as much as it should.

Foolish thoughts
The companies mentioned here are far from frauds, but it doesn't appear that they are doing everything, and in some cases anything, to increase shareholder value. I'm left wondering: Do they really care about you?

What's your take on the fiduciary responsibility of management? Feel free to share your thoughts in the comments section and consider adding these stocks and your personal portfolio to My Watchlist.

Add Tyco International, Protalix BioTherapeutics, Pfizer, Abercrombie & Fitch, Rite-Aid, Apple, and Microsoft to My Watchlist.

Fool contributor Sean Williams does not own shares in any companies mentioned in this article. He prefers to invest in companies that refrain from buying $6,000 toilets. You can follow him on CAPS under the screen name TMFUltraLong. Pfizer and Microsoft are Motley Fool Inside Value selections. Motley Fool Options has recommended a diagonal call position on Microsoft. Apple is a Motley Fool Stock Advisor pick. The Fool has written puts on Apple and owns shares of Microsoft and Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy which always puts investors first.